Pharma Tech Outlook

Critical Role of CDMO in Enhancing Pharmaceutical Development CDMOs enhance pharmaceutical development by providing specialized expertise, infrastructure, and regulatory compliance throughout the drug development lifecycle. Read More: https://lnkd.in/gHDXfQdC #PharmaInnovation #DrugDevelopment #PharmaSolutions

EuroscreenFast has been recognized as one of the Top Pharma Outsourcing Companies in Europe by Pharma Tech Outlook. EuroscreenFast is a contract research organisation with over 30 years of experience pioneering GPCR science, developing and performing functional, cell-based assays to support drug developers in discovering and optimising new therapies. The services include custom cell lines and assay development, high-throughput screening, deorphanisation and preclinical profiling of drug compounds for effectiveness and safety. “Our goal always has been to ensure clients feel secure, knowing we will deliver exceptional service and care for their projects as though they were our own internal R&D programs, with the highest data quality in the shortest time. This is unmatched customer service,” says Dr. Laurent Meeus, chief scientist and general manager. The article will also be featured in the forthcoming special print edition on Pharma Outsourcing 2024. Read More: https://lnkd.in/eHM_2bi3 #BiotechInnovation #PharmaceuticalResearch #BiotechExperts #HealthcareInnovation #PharmaBreakthroughs

JS Biosciences Co., Ltd. has been recognized as one of the Top Pharmaceutical Outsourcing Services Companies in Apac by Pharma Tech Outlook. JSBio delivers superior cell culture media formulations and development services. Serum-free cell culture media can notably improve consistency and efficacy, minimize contamination risks, and simplify downstream processes. With proprietary technology, JSBio facilitates suspension adaptation of adherent cells, enabling most suspension cell lines to grow in serum-free environments. “We pride ourselves on our industry-leading lead time of 30-45 days, ensuring a seamless transition from small to large scales with our flexible dry powder capacity. Our lot-to-lot consistency guarantees reliable and consistent product quality,” says Dr. Luo. Read More: https://lnkd.in/gHgkZADF #CellCultureMedia #BiotechInnovation #LabSupplies #BiotechLeadership #ResearchSolutions

ARISTA Corporation has been recognized as one of the Top Pharma Manufacturing Solutions Providers by Pharma Tech Outlook. ARISTA is a leading provider of computing platforms and visualization display products for pharma manufacturing organizations. All products, including rugged computing platforms, mobile workstations, touch panels and displays for industrial automation, are built with SS316L NEMA 4X / IP66 stainless steel enclosure to meet the highest hygiene standards of the industry. “Rather than just selling standard products, we take a customer-centric approach that drives clients toward lasting success by establishing strong, positive business relationships,” says Paul Shu, owner. The article will also be featured in the forthcoming special print edition on Pharma Manufacturing 2024. Read More: https://lnkd.in/guzFMHp2 #ManufacturingExcellence #CustomWorkstations #MobileWorkstations #IndustrialDesig #EfficiencyInProduction

JS Biosciences Co., Ltd. has been recognized as one of the Top Pharmaceutical Outsourcing Services Provider in Apac by Pharma Tech outlook. JSBio delivers superior cell culture media formulations and development services. Serum-free cell culture media can notably improve consistency and efficacy, minimize contamination risks, and simplify downstream processes. With proprietary technology, JSBio facilitates suspension adaptation of adherent cells, enabling most suspension cell lines to grow in serum-free environments. “We pride ourselves on our industry-leading lead time of 30-45 days, ensuring a seamless transition from small to large scales with our flexible dry powder capacity. Our lot-to-lot consistency guarantees reliable and consistent product quality,” says Dr Shun Luo, Chairman and President. Read More :https://lnkd.in/gHgkZADF #CellCultureMedia #BiotechInnovation #Biotechnology #LabTechnology #ScientificResearch

Luckie & Company Named One of North America's Top 100 Healthcare Marketing Agencies Medical Marketing + Media (MM+M) released their annual ranking of the top 100 healthcare marketing firms in North America and Luckie has been named to the 2024 list. The MM+M Agency 100 includes medical marketing agencies that range from boutique shops to global networks, putting Luckie among the most accomplished marketers in the healthcare industry. Read More: https://lnkd.in/gKk4iMM7 #HealthcareMarketing #Top100Agencies #MarketingExcellence #IndustryLeaders #LuckieAndCo

Boston, are you ready? Pharma & Patient USA 2024 is coming for you! Our first patient co-curated agenda has finally arrived. See the first release of event highlights, this year's industry leading speaker line-up and agenda here: https://bit.ly/3Vz5BAe   This leading conference is where you will engage with industry changemakers to learn first-hand how to drive change that will build a brighter and more inclusive future in healthcare that empowers ALL patients.   Are you ready to be the new beacon of trust? Join us to be in the room, be visible and be engaged.    #REpatientUSA

Frontage Labs has been recognized as one of the Top CRO by Pharma Tech Outlook. Frontage is a global leader in pharmaceutical services, offering comprehensive solutions across all drug development stages. It accelerates innovation for life-changing treatments with its expertise in delivering chemistry, bio-analysis and preclinical services. “We aim to be the one-stop shop for our clients, offering holistic support from drug discovery to clinical trials,” says Dr. John Lin, president at Frontage Labs. The article will also be featured in the forthcoming special print edition on CRO 2024. Read More : https://lnkd.in/g-Y5JVGm #drugdiscovery #clinicaltrials #regulatoryconsulting #pharmadevelopment

ChemoGenics BioPharma has been recognized as one of the Top Drug Discovery and Development Solutions Provider by Pharma Tech Outlook. Started as a service-based organization, ChemoGenics has a long-term vision of leveraging its extensive knowledge base and expertise in drug discovery to help peers in biological sciences to identify molecules that confirm biological hypothesis and advance to the next phase of lead to candidate selection. “In essence, its collaborators don’t need external consultants to address different aspects of drug discovery as the company is well-resourced to help clients reach IND-enabling studies,” says Francis Tavares, President and CEO of ChemoGenics BioPharma. The article will also be featured in the forthcoming special print edition on Drug Discovery and Development 2024. Read More : https://lnkd.in/dRYhFVGS #drugdiscovery #leadoptimization #clinicaltrials

BioPharma Services has been recognized as one of the Top CRO by Pharma Tech Outlook. BioPharma Services stands out as a CRO due to its ‘protocol champion’ approach. Scientists are deeply involved in every stage of your clinical trial, ensuring scientific integrity and smooth operation. It collaborates closely with project managers for seamless communication and swift problem-solving. BioPharma embraces unique challenges, adapting its processes to client needs. Its expertise in CNS research makes it a valuable partner, particularly for complex or unconventional trials like those involving psychedelics. “Instead of relying on outside consultants who may not fully understand the complex nuances of early-stage trials, our Protocol Champions remain deeply involved in every stage of a study—optimizing the research design,” says Dr. John Oldenhof, Executive VP of Scientific Affairs. The article will also be featured in the forthcoming special print edition on CRO 2024. Read More : https://lnkd.in/d9HYWVA2 #scientificintegrity #drugdevelopment #trialinnovation